Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now later-stage tilt small index

Papillomavirus Infection: later-stage trial registry

3 of 4 indexed Papillomavirus Infection trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count

Papillomavirus Infection: 4 US clinical trials tracked, 3 recruiting.

Papillomavirus Infection is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Louisiana State University Health Sciences Center in New Orleans, running 1 of these trials.

Enrollment posture brief

Registry condition papillomavirus-infection

OPEN 3 | RECR 75% | LATE 2 | EARLY 1 | RANK #4115 | SPON 1

Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)

Ablation80%ACL Reconstruction80%Papillomavirus Infection (th…75%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Papillomavirus Infection

Papillomavirus Infection lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Papillomavirus Infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Papillomavirus Infection is recruiting above its size-band peers.

    3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 42

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 4 2

Named interventions

Most-linked intervention names on Papillomavirus Infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

COPAN 552c.80 FLOQSwab Device
1 trials
human papillomavirus vaccine, recombinant Biological
1 trials
Human papillomavirus 9-valent vaccine, recombinant Biological
1 trials
STAR0602 Drug
1 trials
Zopapogene imadenovec (Zopa) Drug
1 trials

US sites by state

Facility locations filed on Papillomavirus Infection trials. A trial with sites in several states counts in each.

Ohio 2 trials
Maryland 2 trials
Wisconsin 1 trials
Washington 1 trials
Texas 1 trials
Tennessee 1 trials
Oklahoma 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Papillomavirus Infection page

4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Papillomavirus Infection condition card totals 4 registered trials; most-linked intervention COPAN 552c.80 FLOQSwab; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.